Aspirin Reloaded.

[Argirios Argiriou]

06/08/2014.
του Διαμαντή Κλημεντίδη.

Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

[Argirios Argiriou]

May 6, 2014
Journal Watch.

By Larry Husten.

Aspirin shouldn't be marketed for primary prevention of heart attack or stroke, the FDA has announced. The statement follows the agency's rejection on Friday of Bayer Healthcare's decade-old petition requesting approval of a primary prevention indication.

Aspirin is still widely used for primary prevention. The American Heart Association currently supports its use for primary prevention when recommended by a physician in high-risk patients. (There is widespread agreement that for secondary prevention, aspirin's benefits outweigh the risks, and it should be used to prevent a second heart attack or stroke after an earlier cardiovascular event.)

In its statement, the FDA said it had "reviewed the available data and does not believe the evidence supports the general use of aspirin for primary prevention of a heart attack or stroke. In fact, there are serious risks associated with the use of aspirin, including increased risk of bleeding in the stomach and brain."
Link(s):

FDA consumer information (Free)

Background: NEJM Journal Watch General Medicine coverage of USPSTF recommendations on aspirin use (Your NEJM Journal Watch registration required)

- See more at: Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

[Argirios Argiriou]

23 January 2019

A new meta-analysis of trials evaluating aspirin for primary prevention of cardiovascular disease has found no overall benefit, with aspirin use associated with a lower risk of cardiovascular events but an increased risk of major bleeding, and no effect of aspirin on cancer risk.

However, there still appears to be some disagreement on how to apply these findings.

Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

[Argirios Argiriou]

Marco Valgimigli

DISCLOSURES Eur Heart J. 2019;40(7):618-620.

The Remarkable Story of a Wonder Drug, Which Now Comes to an End in the Primary Prevention Setting: Say Bye-bye to Aspirin!

Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

[Argirios Argiriou]

14 June 2019.

#JACC Editors’ Insights: Do you prescribe aspirin for the primary prevention of cardiovascular events? New meta-analysis examined 15 randomized clinical trials featuring a total of 165,502 participants to evaluate outcomes with aspirin use for primary prevention. Δεν είναι ορατοί οι σύνδεσμοι (links). Εγγραφή ή Είσοδος

[Ορθοπαιδικός]

.
#JACC Editors’ Insights: Do you prescribe aspirin for the primary prevention of cardiovascular events? New meta-analysis ....

   Και το συμπέρασμα του εκδότη; (""Conclusions Aspirin for primary prevention reduces nonfatal ischemic events but significantly increases nonfatal bleeding events""). Να δίνουμε ή όχι ασπιρίνες; Ή η εργασία του σταματά στη καταμέτρηση μόνο των περιστατικών;
   Υπάρχει κανείς που θα πληρώσει 35$ για ένα άρθρο. Πόσο θα κάνει τότε το περιοδικό;